Search results
Results from the WOW.Com Content Network
Tumor characteristics: Tumors with a high cell turnover rate, rapid growth rate, and high tumor bulk tend to be more associated with the development of tumor lysis syndrome. The most common tumors associated with this syndrome are poorly differentiated lymphomas (such as Burkitt's lymphoma ), other Non-Hodgkin Lymphomas (NHL), acute ...
Laboratory findings may show abnormally low white blood cell, red cell counts, and platelet counts. In addition, serum uric acid and lactate dehydrogenase levels may be elevated, while serum calcium levels may be decreased. All of these findings together can suggest tumor lysis syndrome. [citation needed]
It is an acute syndrome requiring aggressive cytoreductive modalities including chemotherapy and/or leukapheresis to both reduce the number of circulating leukocytes and to break apart any aggregates that have already formed. Such rapid and massive lysis of tissue poses a risk of complications (tumor lysis syndrome), but it is necessary to ...
In particularly large tumors and cancers with high white cell counts, such as lymphomas, teratomas, and some leukemias, some people develop tumor lysis syndrome. The rapid breakdown of cancer cells causes the release of chemicals from the inside of the cells. Following this, high levels of uric acid, potassium and phosphate are found in the blood.
Kidney failure, treatment induced, tumor lysis syndrome, seizures, prolonged ischemia [1] [2] Diagnostic method: Blood level > 1.1 mmol/L (2.6 mg/dL) [1] [3] Differential diagnosis: Kidney failure, high blood calcium, high blood potassium, hypoparathyroidism, hypothyroidism, lithium toxicity, red blood cell breakdown, rhabdomyolysis [4] Treatment
The disease is restricted to individuals with Down syndrome or genetic changes similar to those in Down syndrome, develops in a baby during pregnancy or shortly after birth, and resolves within 3 months or, in ~10% of cases, progresses to acute megakaryoblastic leukemia. Transient myeloid leukemia is a pre-leukemic condition.
Rasburicase is approved for use by the U.S. Food and Drug Administration (and European counterparts) for the prevention and treatment of tumor lysis syndrome (TLS) [6] in people receiving chemotherapy for hematologic cancers such as leukemias and lymphomas. However, it is not clear if it results in important benefits such as decreased kidney ...
Cardiac arrest, cytokine release syndrome, tumor lysis syndrome and acute kidney injury, infections, [14] hepatitis B reactivation, immune toxicity, pulmonary toxicity, [15] bowel obstruction and perforation [16] [17] [18] Trastuzumab (Herceptin) A monoclonal antibody against HER2/neu (erb-B2). Helps kill breast cancer cells that overexpress ...